6-((4-phenylpiperidin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one | 1246081-99-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-((4-phenylpiperidin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
• 英文别名: 6-[(4-phenylpiperidin-1-yl)methyl]-4H-1,4-benzoxazin-3-one
• CAS: 1246081-99-1
• 化学式: C₂₀H₂₂N₂O₂
• 分子量: 322.407
• InChiKey: STRLBVZWHPHNQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羟基-3-硝基苯甲醛 在 三乙酰氧基硼氢化钠 、 铁粉 、 potassium carbonate 、 溶剂黄146 作用下， 以 溶剂黄146 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 6-((4-phenylpiperidin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
  参考文献：
  名称：

  Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors

  摘要：

  Structure based drug design of a series of novel 1,4-benzoxazin-3-one derived PARP-1 inhibitors are described. The synthesis, enzymatic 82 cellular activities and pharmacodynamic effects are described. Optimized analogs demonstrated inhibition of poly-ADP-ribosylation in SW620 tumor bearing nude mice through 24 h following a single dose. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.055

文献信息

• POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
  申请人：Brown Jason W.

  公开号：US20120094992A1

  公开（公告）日：2012-04-19

  Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.

  以下式子的化合物被提供用于抑制Poly (ADP-ribose) Polymerase (PARP)的作用： 其中变量在此定义。还提供了制备该化合物的药物组合物、工具箱和制造品、中间体的方法以及使用该化合物的方法。
• Poly (ADP-ribose) Polymerase (PARP) Inhibitors
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2415767A1

  公开（公告）日：2012-02-08

  The invention provides compounds of the general formula (1): wherein the variables are as defined herein. The compounds have use in inhibiting poly (ADP-ribose) Polymerase (PARP). The invention also provides pharmaceutical compositions containing the compounds and their use as medicaments.

  本发明提供通式（1）的化合物： 其中的变量如本文所定义。这些化合物可用于抑制聚（ADP-核糖）聚合酶（PARP）。本发明还提供了含有这些化合物的药物组合物及其作为药物的用途。
• US8669249B2
  申请人：——

  公开号：US8669249B2

  公开（公告）日：2014-03-11
• [EN] POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS<br/>[FR] INHIBITEURS DE LA POLY(ADP-RIBOSE)POLYMÉRASE (PARP)
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010111626A2

  公开（公告）日：2010-09-30

  Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.
• Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors
  作者：Anthony R. Gangloff、Jason Brown、Ron de Jong、Douglas R. Dougan、Charles E. Grimshaw、Mark Hixon、Andy Jennings、Ruhi Kamran、Andre Kiryanov、Shawn O’Connell、Ewan Taylor、Phong Vu

  DOI：10.1016/j.bmcl.2013.06.055

  日期：2013.8

  Structure based drug design of a series of novel 1,4-benzoxazin-3-one derived PARP-1 inhibitors are described. The synthesis, enzymatic 82 cellular activities and pharmacodynamic effects are described. Optimized analogs demonstrated inhibition of poly-ADP-ribosylation in SW620 tumor bearing nude mice through 24 h following a single dose. (c) 2013 Elsevier Ltd. All rights reserved.